Navigation Links
Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference
Date:12/7/2009

DOYLESTOWN, Pa., Dec. 7 /PRNewswire/ -- Patricia Scheller, CEO of Prescient Medical, Inc., will be among the speakers at the Galen Institute's "The Value of Innovation in Health Care" conference. The conference will take place on Wednesday, December 9th in Washington DC at the Columbus Club at Union Station.

The Galen Institute is a non-profit public policy research organization focusing on health and tax policy.

"I'm very pleased to be part of the Galen Institute's conference," said Ms. Scheller. "As the debate on health care reform continues, there appears to be bipartisan agreement that continued innovation in medical research and the development of pioneering medical technology is critical. The US has historically led the world in advancing medical progress and the policy initiatives being discussed have the potential to profoundly impact our future position. The Galen Institute's conference offers a wonderful opportunity to provide input to lawmakers on how their policies can promote innovation."

The event unites policy experts, elected officials, and leaders in a number of health care-related industries to discuss the effects of health care reform on innovation. Prescient Medical has developed two breakthrough interventional cardiology solutions: the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System.

The vProtect(TM) Luminal Shield is a novel self-expanding coronary stent-like Shield that received CE Mark certification in August, 2009, allowing it to be marketed in Europe for improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease. The Shield was recently honored with Frost & Sullivan's 2009 North American Product Innovation of the Year Award. Designed specifically to minimize arterial injury and its consequences, the Shield is ideal for treating softer plaques, such as those that are typically associated with heart attacks.

The vPredict(TM) Optical Catheter System is being developed for the detection and characterization of soft plaque. Its technology platform is based on Raman spectroscopy, a highly sensitive technique proven in numerous non-clinical applications. The vPredict(TM) System detects clinically important compounds, including cholesterols, in the vessel wall and plaque. The goal of the vPredict(TM) System is to provide physicians with information to identify patients at risk for a heart attack and treat them proactively.

For more information on Prescient Medical or its products, please contact Ilana Odess, General Manager of Prescient Medical, at: iodess@pmivp.com.

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. The company is the recipient of the 2009 Frost and Sullivan Award for Product Innovation of the Year Award for vProtect(TM) Luminal Shield. For more information about Prescient Medical and its products, please visit www.prescientmedical.com.

SOURCE Prescient Medical, Inc.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prescient Medical vProtect(TM) Luminal Shield Receives North American Product Innovation of the Year Award from Frost & Sullivan
2. Prescient Medical Inc. Featured on FOX Business Network
3. vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark
4. Prescient Medical Receives Frost & Sullivan Product Innovation of the Year Award
5. Momentum Women(TM) Honors Patricia Scheller of Prescient Medical for Commitment to Promoting Cardiovascular Disease Awareness
6. Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California)
7. Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc.
8. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
9. Solta Medical, Inc. Appoints Jeffrey Nardoci Vice President of Global Marketing
10. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
11. China Sky One Medical, Inc. Exports Pain Relief Patch to Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/25/2017)... ... 2017 , ... FCPX users now have the ability to sharpen a desired ... Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical ... tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – ... Private has initiated a second print-run of its lavish luxury travel coffee table book. ... open, weighs in at more than six kilos, retails at EUR 1,000 per copy ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of ... critically important that we all are aware of our options and are empowered ... to announce the launch of its newest edition of "Vision and Hearing" in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology: